Digital Diabetes Management Market by Product (Device (Smart Glucometer, CGM, Insulin Patch Pump), Diabetes Apps, Service, Data Management Software), Device Type (Handheld & Wearables), End User (Hospitals & Self/home healthcare) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Digital Diabetes Management market size was estimated at USD 14.7 billion in 2022 and is expected to surpass around USD 30.5 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 15.2% during the forecast period 2022 to 2030.

The robust growth of the market is majorly attributed to the growing prevalence of diabetes, coupled with technological advancement and innovation. For instance, according to the International Diabetes Federation, approximately 536,600 adults were living with diabetes in 2021 and this number is expected to reach 783,700 in 2045. As digital technology is continuously advancing, the market is expected to witness a wide range of innovations within the diabetes space, which has the potential to change the way we manage the disease. The number of smartphone apps available for the management of the disease has increased over the last few years, and there are over a hundred apps available on web-based app stores that can help patients monitor their blood glucose levels.

The rapidly changing lifestyles such as smoking and consumption of alcohol are contributing to the rise in the number of diabetes patients worldwide. Moreover, obesity is one of the major factors contributing to diabetes. The market for diet and weight management apps is showing great potential with the growing obese population, coupled with increasing awareness among patients.

Diabetes is a clinical condition where the inability of the pancreas to produce insulin causes an increase in glucose levels in the body. Diabetic patients face many daily challenges such as knowing what to eat, understanding medical advice, and the impact of food and activity on sugar. The anytime-anywhere nature of digital technology enables patients to address their health issues by connecting with the healthcare team and sharing data. This is creating a digital ecosystem of data-driven tools that can connect patients and their care team for better management of diabetes.

The COVID 19-pandemic has positively impacted the growth of the digital diabetes management devices market. The management of blood glucose levels became a critical task for patients admitted to hospitals with severe lung infections. Medications used to treat the disease led to a significant change in patient blood glucose levels. Moreover, the Center for Disease Control and Prevention highlighted that people who are living with diabetes and have been diagnosed with COVID-19 were admitted to critical care. Hence, the need for using diabetes management devices significantly increased.

Digital Diabetes Management Market Dynamics:

Drivers :

According to the WHO, diabetes is expected to become the seventh-leading cause of death by 2030. The major risk factors for diabetes include stress, sedentary lifestyles, unhealthy diets, and obesity. Aging-related physiological changes are also a significant contributor to the risk of diabetes. For instance, according to the International Diabetes Federation, diabetes prevalence increases with age. Thus, the highest estimated prevalence is in people older than 65 years.

Diabetes estimates for 2021 show an increasing prevalence of diabetes by age. Similar trends are estimated for 2045. Diabetes prevalence is lowest among adults aged 20–24 years (2.2% in 2021). Among adults aged 75–79 years, diabetes prevalence is estimated to be 24.0% as of 2021 and is estimated to increase to 24.7% by 2045. These data point to a significant increase in the diabetes population in countries with large geriatric populations in the next 25 years. Therefore, the growing geriatric population, coupled with the increasing population exposure to key risk factors, is expected to drive the demand for digital diabetes management solutions across major markets.

Technological advancements

In the last decade, the medical devices sector has witnessed significant technological advancements in the field of diabetes care, including the emergence of focused sensor-based CGM technology, implantable digital diabetes management devices, closed-loop systems, and wearable smartphone-based diabetes management devices. Technologically advanced systems have improved the ability to manage diabetes and made it practical to achieve tight control while providing a more flexible schedule and diet for patients, children, and their families. Several digital diabetes management solutions currently available are competitive compared to their conventional counterparts, such as prefilled syringes, glucose meter analogs, test strips, and insulin pumps.

Newer digital solutions are being introduced that are more convenient than traditional diabetes management therapies or even previous iterations or counterparts. With the launch of the FreeStyle Libre and Dexcom G5 CGM, for example, devices are facilitating minimally invasive and accurate glucose monitoring. Non-invasive connected sensor developments have been vital in increasing the accuracy of monitoring blood glucose levels and the longevity of the CGM device, as in the case of Eversense XL by Sensionics (that can last up to 180 days). Similarly, skin patches, gas sensors, radio-wave technology, and microneedles are used as minimally invasive methods.

Combination and integrated approaches for the monitoring and management of diabetes are gaining in popularity, apart from standalone devices. These devices can not only provide remote monitoring but also help in providing connected care that is continuous, modular, and targeted. Besides this, smart contact lenses integrated with biosensors and drug delivery materials are being researched for use in CGM, as well as to treat diabetic retinopathy.

Growing adoption of cloud-based enterprise solutions for diabetes management

Improving connectivity and computing power have considerably increased the reach—while decreasing the cost—of medical data sharing, enabling significantly higher levels of patient communication and treatment decision support. Automated uploads through the cloud minimize effort on the part of patients and clinicians, enabling universal, real-time access to data.

In terms of diabetes management, the adoption of cloud-based solutions allows for near-constant monitoring of blood glucose levels; data can be stored safely in the cloud and easily retrieved. Physicians can also view and maintain the patient’s history and test results and prescribe medication through mail or mobile messages based on the latest blood glucose levels. This reduces the burden on healthcare providers and leads to more efficient disease management. With automated transfer to apps and online diabetes data management software, glucose data is made easily accessible during appointments.

Some cloud-based enterprise solutions for diabetes management include Rimidi by Rimidi Diabetes Inc. (US), GlucoMe solution by GlucoMe (Israel), iGlucoCheck by ALTEN Calsoft Labs (US), Diamond by Hicom (UK), One Drop by Informed Data Systems Inc. (US), and eGMS by Glytec LLC (US).

Use of artificial intelligence in diabetes care devices

Artificial intelligence (AI) is a fast-growing field, and its applications in diabetes have reformed the approach to the diagnosis and management of this chronic condition. Principles of machine learning have been used to build algorithms to support predictive models for the risk of developing diabetes or its consequent complications.

Digital therapeutics have proven to be an established intervention for lifestyle therapy in the management of diabetes. Patients are increasingly being empowered for the self-management of diabetes, and both patients and healthcare professionals are benefitting from clinical decision support. AI allows continuous and burden-free remote monitoring of patients’ symptoms and biomarkers. Furthermore, social media and online communities enhance patient engagement in diabetes care.

Technical advances have helped to optimize resource use in diabetes. Together, these intelligent technical reforms have produced better glycemic control with reductions in fasting and postprandial glucose levels, glucose excursions, and glycosylated hemoglobin. AI will introduce a paradigm shift in diabetes care from conventional management strategies to building targeted data-driven precision care. Livongo Health (US), for example, is using a big-data-enabled approach to help people manage their health and improve their lifestyles. Several people are using the company’s innovative products, including blood glucose meters, blood pressure cuffs, and scales, which have the ability to collect data and send it to a larger database. This data is subsequently used by the company to generate comprehensive insights for the benefit of patients.

Restraints :

The cost of insulin delivery devices, such as smartphone-connected insulin pumps, is ~USD 4,500–6,500. Moreover, the average selling price of sensor-based continuous glucose monitors is USD 1,000–1,400, with sensors requiring replacement every few days. Digital self-monitoring blood glucose meters cost around USD 15–20. Given the high initial cost and the frequent use of associated consumables (requiring repeated purchase), this puts advanced devices out of reach for a large portion of end users—particularly those in developing countries with an unfavorable reimbursement scenario.

In developed countries, the cost of currently marketed devices is covered under most commercial health plans; in developing countries, disparities in reimbursement policies often result in non-compliance to treatment. In China and India, patients with diabetes are required to entirely bear the expenses for blood glucose monitors, insulin, integrated CGM systems, and their maintenance. Consequently, the high costs and lack of reimbursements in developing countries can be expected to limit the adoption of digital diabetes management solutions in the coming years.

Higher acceptance of traditional diabetes management devices

Patients in many geographical areas still prefer traditional ways to manage diabetes. There are many patients that avoid digital platforms and prefer traditional blood glucose readers and glucose strips, insulin injections, prefilled syringes, and drug therapy due to their low cost and a lack of knowledge about connected devices and apps. The low adoption of smartphones, tablets, and computers for diabetes management in some countries has also affected the acceptance of advanced technologies.

Most available apps and platforms are not being used by elderly patients, non-English speakers, and the physically challenged. This is particularly evident in Asia Pacific, Middle Eastern, and African countries, where low awareness, lack of trained personnel, and unfavorable/negligible reimbursements have affected the use of digital diabetes management. In China and India, reliance on alternative traditional diabetes management practices, such as herbal medicines, is also restraining the market growth.

Opportunities :

The increase in global health expenditure due to diabetes has been considerable, growing from USD 232 billion in 2007 to USD 966 billion in 2021 for adults aged 20–79 years. This represents a 316% increase over 15 years. Part of this increase can be attributed to improved data quality. The direct costs of diabetes are expected to continue to grow. The IDF estimates that total diabetes-related health expenditure will reach USD 1.03 trillion by 2030 and USD 1.05 trillion by 2045 (Source: IDF Atlas 2021). The North America and Caribbean region has the highest diabetes-related health expenditure per adult with diabetes (USD 8,209), followed by the Europe region (USD 3,086), South and Central America region (USD 2,190), and WP region (USD 1,204). This figure is USD 465 per person with diabetes in the Middle East and North Africa region, USD 547 in the Africa region, and USD 112 in the Southeast Asia region. Expenditure due to diabetes has a substantial impact on total health expenditure worldwide, representing 11.5% of the total global health spending. Considering the increasing diabetes-related health expenditure in emerging countries, many digital diabetes management device manufacturers are focusing on expanding their business in these markets to capitalize on new opportunities.

Challenges:

The penetration of technologically advanced digital diabetes management platforms is comparatively less in developing countries as opposed to developed countries. This is attributed to the inadequate infrastructure, unclear nationwide e-health agendas, the need to overcome public uncertainty over data privacy and security, difficulties in achieving interoperability, lack of a trained workforce in health informatics (and existing initiatives for its development), and fewer strategies to achieve regional integration.

In developing countries, low levels of private and public financial resources are spent on health, which affects access to healthcare as well as the quality of the health system. According to a WHO and World Bank report, as of 2021, 480 million people do not have access to essential health services (mostly in Africa and South Asia). Poor access and quality and low levels of digitization have negative implications on not only key health outcomes but also the poverty rate. The result is a general reluctance and inability to fully adopt advanced solutions, including those for digital diabetes management.

Lack of data security

Security concerns related to proprietary data and applications are considered a major hindrance to the growth of the digital diabetes management market. Since digital diabetes management is an emerging market, there are no standard frameworks to secure the data stored and shared using diabetes care apps and platforms. One of the major risks of using diabetes care apps is the theft of Protected Health Information (PHI), such as health insurance data, by third parties who can commit healthcare fraud using confidential information. On the other hand, several organizations do not possess the resources required to secure these technologies.

Since mobile phones play a critical role in such smart applications and platforms, the simple loss or theft of a mobile device loaded with unencrypted patient data can result in a security breach with serious consequences. In the US, such privacy breaches could lead to enforcement actions by the Department of Health and Human Services (HHS) under the Health Insurance Portability and Accountability Act (HIPAA). Many countries across the globe also have national or regional regulations against data breaches and healthcare frauds. Consequently, although digital diabetes management solutions offer various advantages, the associated security issues may slow the adoption of mobile technology in diabetes management..

“Continuous Glucose Monitoring (CGM) systems segment to grow at the highest CAGR during the forecast period.”

Various products and services considered in the digital diabetes management market are devices, apps, data management software & platforms, and services. The devices segment consist of smart glucose meters, continuous glucose monitoring (CGM) systems, smart insulin pens, and smart insulin pumps/closed-loop systems & smart insulin patches. Similarly, the apps segment is further classified into diabetes & blood glucose tracking apps and obesity & diet management apps. The continuous glucose monitoring systems market is expected to grow at the highest CAGR during the forecast period. This is mainly because these systems are minimally invasive as compared to conventional blood glucose meters.

“Wearable devices segment held the largest share in the Digital Diabetes Management market in 2021.”

Based on type, the digital diabetes management devices market is segmented into handheld devices and wearable devices. Wearable devices accounted for the largest share of 60.3% of the digital diabetes management devices market in 2021. These devices include CGM systems, smart insulin pumps, and smart insulin patches. Increasing awareness about glucose monitoring; the increasing number of regulatory approvals for CGM systems; technological advancements such as closed-loop pump systems, smart insulin patches, and other pipeline devices are some of the major factors propelling the demand for wearable devices for diabetes management. Also, connected devices provide instant access to glucose-level readings at periodic intervals, enable dose management and recording, and allow patients to upload data online at home.

“The Self/home healthcare segment to grow at the fastest CAGR during the forecast period”

The major end users of the digital diabetes management market are self/home healthcare, hospitals & specialty diabetes clinics, and academic & research institutes. The self/home healthcare segment is projected to grow at the highest CAGR of 13.2% during the forecast period. Technological advancements in self/home care digital diabetes management systems and platforms have made them more accurate, minimally invasive, and easy to use. The introduction of CGM systems, insulin pump therapy, applications, and services has increased the demand for non-invasive or minimally invasive systems in home care.

Regional Insights

North America dominated the market in 2021 with a revenue share of over 35.4% due to the availability of advanced technologies and the recent approval of many digital blood glucose patient monitoring devices. For instance, in January 2022, Insulet Corporation announced that it has received clearance from the U.S. FDA for its Omnipod 5 Automated Insulin Delivery System, which integrates with Dexcom G6 Continuous Glucose Monitoring (CGM). It facilitates remote patient monitoring and data transfer through Omnipod 5 mobile app with its integrated SmartBolus Calculator. Furthermore, the increasing geriatric population and the growing burden of diabetes due to lifestyle changes are expected to boost the market growth.

Asia Pacific is expected to witness exponential growth during the forecast period owing to new product launches, a large diabetes population base, and increasing government initiatives. For instance, in January 2022, The Australian Centre for Accelerating Diabetes Innovation (ACADI) at the University of Melbourne announced that it would be granted USD 10 million over 4 years by the federal government. The ACADI will be a new virtual research center that will connect research centers around Australia and help important industry partners and organizations in the development of new therapies, technology, and behavioral interventions to address issues related to diabetes in the country.

Some of the prominent players in the Digital Diabetes Management Market include:

Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), Tandem Diabetes Care (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), One Drop (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Decide Clinical Software GmbH (Austria), Pendiq GmbH (Germany), and BeatO (India).

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Digital Diabetes Management market

By Product & Service

• Devices
• Smart Glucose Meters
• Continuous Glucose Monitoring (CGM) Systems
• Smart Insulin Pens
• Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches
• Application
• Diabetes & Blood Glucose Tracking Apps
• Obesity & Diet Management Apps
• Data Management Software & Platforms
• Services

By Device Type

• Handheld Devices
• Wearable Devices

By End User

• Self/Home Healthcare
• Hospitals & Specialty Diabetes Clinics
• Academic & Research Institutes

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Digital Diabetes Management Market Study:

• Growth of Digital Diabetes Management in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Digital Diabetes Management and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Digital Diabetes Management Consumption Analysis
•  Digital Diabetes Management Production Analysis
•  Digital Diabetes Management and Management